Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease
Stopped early · Phase 1 · Has a placebo group
Conditions studied: Alzheimer Disease
In brief
The primary purpose of this study is to assess biomarker known as amyloid beta peptide 40 (Ab40) in Cerebrospinal Fluid (CSF), following a single oral dose of PAZ-417 in subjects with Alzheimer Disease (AD). This study will also consider another biomarker amyloid beta peptide 42 (Ab42) in Cerebrospinal Fluid in subjects with Alzheimer Disease and assess the safety, tolerability and pharmacokinetic profile of PAZ-417 in both plasma and Cerebrospinal Fluid in these subjects.
Key facts
- Study ID
- NCT00739037
- Run by
- Wyeth is now a wholly owned subsidiary of Pfizer
- People needed
- 10
- Starts
- 2008-08-01
- Expected to finish
- 2008-12-01
- Last updated by the study team
- 2009-08-04
Who can join
Age: 55 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- California Clinical Trials — Glendale, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.